Edwards BioPhysio Valve To Solve Stentless Versus Stented Conundrum
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will begin clinical trials this year for its BioPhysio replacement heart valve technology, combining the advantages of the company's stented and stentless tissue replacement valves
You may also be interested in...
Edwards, Cook Biotech Collaborate On Permanent Heart Valve Replacement
Edwards Lifesciences intends to use Cook Biotech's small intestinal submucosa (SIS) technology to create the first permanent replacement heart valve under a worldwide licensing/supply deal
CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring
CardioFocus expects its Light Ring catheter to be among the first devices to cure drug-resistant paroxysmal atrial fibrillation (AF) in patients not indicated for surgery
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.